Shoko Norimura

Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more.

M. Ohtani, H. Houchi, H. Yokomise, 2013, Molecular and clinical oncology.

Indication of metronomic chemotherapy for metastatic breast cancer: Clinical outcomes and responsive subtypes.

M. Ohtani, H. Houchi, H. Yokomise, 2016, Molecular and clinical oncology.

Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer

R. Haba, A. Yamauchi, M. Ohtani, 2013, Cancer biology & therapy.

Status and prognostic value of immunological biomarkers of breast cancer

R. Haba, T. Matsunaga, K. Teramoto, 2023, Oncology letters.

Factors responsible for long-term survival in metastatic breast cancer

M. Ohtani, H. Houchi, H. Yokomise, 2014, World Journal of Surgical Oncology.

[Renal infarction and acute arterial obstruction of the lower extremity encountered after surgery for primary lung cancer].

K. Kenzaki, Shoko Norimura, K. Miura, 2013, Kyobu geka. The Japanese journal of thoracic surgery.